Contineum Therapeutics, Inc. (CTNM): Total Liabilities
$15.65M
As of 2025-12-31
$10.71M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.65M | +5.9% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $14.78M | +159.2% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $5.70M | n/a | 2025-03-06, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $15.65M | +5.9% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $32.02M | +37.2% |
| Annexon, Inc. (ANNX) | 2025-12-31 | $65.92M | +15.7% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $55.04M | +248.4% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $190.57M | -21.6% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $216.01M | -12.8% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $57.16M | -44.6% |
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $23.43M | +14.8% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $130.07M | -6.1% |
Compare CTNM, TNXP, ANNX, ALT side by side · Screen every company in Pharmaceutical Preparations ↗